Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

 | Oct 18, 2017 | 9:29 AM EDT
  • Comment
  • Print Print
  • Print
Stock quotes in this article:






Shares of Spectrum Pharmaceuticals Inc. (SPPI) jumped 34.7% to $19.47 ahead of the market open on Wednesday, Oct. 18, on interim data from a Phase 2 study of poziotinib in EGFR exon 20 mutant non-small-cell lung cancer.

The Henderson, Nev.-based company said the data, which were presented at the 18th IASLC World Conference on Lung Cancer in Japan, showed an objective response rate of 73%.

Meanwhile, shares of FibroGen Inc. (FGEN) rose 3.9% to 57.45 after the China Food and Drug Administration accepted the company's new drug application for registration of roxadustat (FG-4592), a potential treatment for anemia in dialysis-dependent CKD (DD-CKD) and non-dialysis-dependent CKD (NDD-CKD) patients.

The submission of the NDA triggers a $15 million milestone payment by AstraZeneca plc (AZN) to FibroGen.

Among the other biotech stock movers was Halozyme Therapeutics Inc. (HALO) , up 3.9% to $18.43. The San Diego firm said Monday it has started a clinical study of PEGPH20 with atezolizumab (Tecentriq), an anti-PDL1 cancer immunotherapy from Roche Group's Genentech, in patients with previously untreated, unresectable, locally advanced, or metastatic cholangiocarcinoma and gallbladder adenocarcinoma.

Columnist Conversations

Most investors have given up on Vera Bradley (VRA) , but the punishment may not fit the crime, and the company...
When the whole world sells off everybody wants to assign a reason for the action. Today's suggestions: 1...
For the first time since early February the down volume as a percentage of total volume on the NYSE is over 90...



News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.